Skip To Main Content
Sonali P. Barwe on Muck Rack

Sonali P. Barwe

As seen in: Nature, Frontiers, MDPI, Royal Society of Chemistry, BioRxiv, The Journal of Biological Chemistry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sonali P.

Contact Sonali P., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche - Nature Communications

|
By Santhosh Kumar Pasupuleti, Baskar Ramdas, Alan Long, Ramesh Kumar, B. Jacob Kendrick, Ed Simpson, Yunlong Liu, Drew Moore, Suganya Subramanian, Stefano Berto, Sonali P. Barwe, Nai-Kong V. Cheung, Reuben Kapur
| Nature Verified
Abstract Acute myeloid leukemia (AML) patients present with CD8 exhaustion signatures, and pharmacologic inhibition of checkpoints can have therapeutic benefit. The alarmin IL-33 and its receptor STimulation-2 (ST2) promote activation of tissue-regulatory T cells (Treg cells) and accelerate malignant progression in solid tumors, but their role in leukemia remains unclear.
Open in Who Shared Issue with article?

Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway - Nature Communications

|
By Alan Long, Santhosh Kumar Pasupuleti, Baskar Ramdas, Reuben Kapur, Sonali P. Barwe, Nai-Kong V. Cheung
| Nature Verified
Abstract Leukemia stem cells (LSCs) are a small yet powerful subset of leukemic cells that possess the ability to self-renew and have a long-term tumorigenic capacity, playing a crucial role in both leukemia development and therapy resistance. These LSCs are influenced by external and internal factors within the bone marrow niche.
Open in Who Shared Issue with article?

Targeting DLK1 improves survival in patient-derived xenograft models of myeloid leukemia associated with Down syndrome

|
By Sonali P. Barwe, Aimy Sebastian, Meredith Tavenner, Patrick van Berkel
| BioRxiv
Abstract Myeloid leukemia associated with Down syndrome (ML-DS) is a rare pediatric cancer. Current standard-of-care includes cytotoxic chemotherapy. 10-20% of patients develop relapsed leukemia or have refractory disease. These patients have a 3-year event-free survival less than 21%. Novel therapy options are needed to improve survival in these patients with relapsed or refractory disease.
Open in Who Shared Issue with article?
See all 8 articles